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(PS 0-1), never smoker, and development of skin rash with geﬁtinib ( 
p<0.001, p=0.031, p<0.001, respectively). 
Conclusion: This analysis suggests that patients with good perfor-
mance status and never smoker and development of skin rash may 
beneﬁt from geﬁtinib treatment in terms of tumor response as well as 
survival. 
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Background: Geﬁtinib (Iressa) is active as a single agent in the 
treatment of select patients with recurrent non-small cell lung cancer 
(NSCLC). The clinical characteristics of patients treated with geﬁ-
tinib at our department identiﬁed predictive variables associated with 
survival .
Methods: Patients (n = 60) with advanced NSCLC were treated with 
geﬁtinib (250 mg) upon progression with chemotherapy. N-score=o is 
deﬁned as N0,N1 or no-bulky and single N2,N-score=1 is deﬁned as 
bulky or multiple N2 or N3 or distant lymph node.
Results: Partial responses were noted in 18 patients (30%) and disease 
stabilization in 25 (41.7%) patients. The median survival (MS) was 
51weeks and median time to progression was 24 weeks. The predic-
tive factors analyzed were gender,age, tumor histology, T,N, N-score, 
performance status (PS) and weight lost. Tumor histology (p=0.008) 
and N-score (P <0.001)(not N) were predict factors in Cox regression 
model .
Conclusions: Tumor histology and N-score could predict survival time 
for recurrent NSCLC patients treated with geﬁtinib 
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A new class of drugs that have the ability to inhibit the epidermal 
growth factor receptor (EGFR), namely geﬁtinib, erlotinib and cetux-
imab, is being used for treatment of patients with colorectal, head and 
neck, or non-small cell lung cancer (NSCLC) refractory or intolerant to 
chemotherapy.
Erlotinib (EGFR-speciﬁc tyrosine kinase inhibitor) is currently been 
used for the treatment of patients with locally advanced or metastatic 
NSCLC after failure of at least one previous chemotherapy regimen, it 
is taken orally and its most frequent undesirable side-effects are gastro-
intestinal disturbance and, cutaneous alterations (acneiform rash, skin 
dryness, paronychia, nasal or oral ulcers, urticariform rash and sebor-
rhoeic dermatitis), that are observed in 56% and 75%, respectively. 
This skin toxicity is a pharmacologic class effect rather than a hyper-
sensitivity reaction to the drug. It appears to imply a better response 
from the tumor to erlotinib and is dose dependent but not correlated 
with duration of therapy. 
Dermatologists have now the responsibility to assist usage of this new 
therapy without lowering of dosis so an effective oncologic manage-
ment is achieved.
We present 5 cases of patients that underwent erlotinib treatment for 
NSCLC that presented cutaneous alterations, namely an acneiform 
reaction, hirsutism and paronychia and how we manage them. We’ll 
emphasize on cumulative dosis of the drug, delay to the appearance 
of the cutaneous side effects and time needed for their remission after 
treatment. 
This work intends to point out the need for dermatologists to be aware 
of the new oncologic drugs that are being developed, the alterations 
they cause in the skin and the need for a consensus in how to treat them 
so we can help the patient comply with the oncologic treatment and 
hopefully improve its quality of life and survival. 
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Introduction: IMO-2055 is a novel synthetic oligonucleotide ago-
nist of TLR9 that stimulates innate and adaptive immune responses 
in preclinical studies. IMO-2055 was well tolerated in a phase 1 
monotherapy study in refractory solid tumor patients at dosages up to 
0.64 mg/kg/week SC, with optimal immune system activation, based 
on the parameters evaluated, demonstrated between 0.16 and 0.32 
mg/kg/week. Mild, transitory lymphocytopenia on day 2 (d2) was an 
expected pharmacology. Adverse events (AEs) were mild-moderate 
injection site reactions and ﬂu-like symptoms. In preclinical studies, 
IMO-2055 was shown to potentiate the activity of standard oncology 
therapies, including chemotherapy, monoclonal antibodies and targeted 
agents. Combining IMO-2055 with gemcitabine in a mouse NSCLC 
model (A549) led to greater suppression of tumor growth than either 
agent alone. The carboplatin-gemcitabine combination had acceptable 
activity and a different safety proﬁle vs. standard cisplatin-gemcitabine 
in NSCLC (Zatloukal et al, Lung Can 2003). Based on these data, we 
investigated the combination of IMO-2055, gemcitabine and carbopla-
tin in advanced solid tumor patients. 
Methods: We combined IMO-2055 at 4, 8 or 12mg total dose per SC 
injection with gemcitabine 1000mg d1 and 8 IV plus carboplatin AUC5 
d1 IV q3w. The initial IMO-2055 schedule was d1, 8, 15; schedules of 
d2, 9 and d9, 16 were added to optimize IMO-2055 administration rela-
tive to the nadirs of chemotherapy-induced hematological toxicity. Pts 
had refractory solid tumors with ≤ 2 prior regimens and fulﬁlled stan-
dard phase 1 entry criteria. The primary endpoint was to identify MTD; 
secondary endpoints included safety and response rate (RECIST). 
Results: 18 pts were treated from November 2005 to February 2007 for 
a median of 3 cycles (1-15) in 17 evaluable pts (7 male; 10 female): 7 
NSCLC, 3 neuroendocrine, 2 unknown primary, 1 each of melanoma, 
esophagus, head and neck, breast and cholangio- carcinomas. Median 
ECOG PS was 1 (0-1) with median 1 prior chemotherapy and 53% 
prior radiotherapy. Grade 4 neutropenia or thrombocytopenia have 
been identiﬁed as DLTs in 2/5 pts at IMO-2055 12mg d1, 8, 15; 2/3 pts 
at 8mg d2, 9; 1/2 pts at 12mg d9, 16; and 0/3 pts at 8mg d9, 16. Most 
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common treatment related grade 3-4 AEs (n=13) were: thrombocytope-
nia (54%) and neutropenia (46%), with no treatment-related deaths. Of 
16 pts withdrawn, 11 had progression and 5 had chemotherapy delay or 
AEs. 5/7 pts with NSCLC completed 6 cycles and 4 are alive at 11.5-14 
months. One NSCLC patient had an investigator-conﬁrmed partial 
response before progression with brain metastases after 15 cycles. 
Conclusions: The IMO-2055-chemotherapy combination showed signs 
of efﬁcacy in moderately pretreated NSCLC patients. All DLTs in this 
study were hematological and could be attributed to the chemotherapy 
alone, as indicated in a previous report of gemcitabine-carboplatin in 
ﬁrst line pts (34% grade 3/4 neutropenia and 28% grade 3/4 thrombo-
cytopenia) (Zatloukal P et al, ASCO 2002). The absence of hemato-
logical DLTs in the IMO-2055 8mg d9, 16 schedule is encouraging. 
Recruitment continues for the IMO-2055 12mg d9, 16 schedule. IMO-
2055 warrants consideration for additional study in NSCLC.
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Background: The standard treatment for patients with unresectable 
or locally advanced NSCLC is radiotherapy. Erlotinib (Tarceva®) is 
an oral EGFR TKI, that has shown activity in recurrent and metastatic 
NSCLC. This phase II study aims to assess and compare the toxicity 
and activity of the addition to Erlotinib to radiotherapy.
Methods: Patients with stage IA-IIIB medically inoperable or unresect-
able NSCLC, good performance status, measurable disease by RECIST 
criteria, and written informed consent were enrrolled into this prospec-
tive randomized phase II study. Arm A consisted in thoracic 3D radio-
therapy (66Gy in 33 fractions during 6 weeks). Arm B was Erlotinib 
150 mg po qd starting and given concurrently with 3D radiotherapy 
(66Gy in 33 fractions during 6 weeks). Treatment with Erlotinib was 
maintained for 6 months.
Results: A total of 17 pts have been randomized from March 2006 to 
the moment of this analysis.
Complete data for 13 pats are available (8 Arm A, 5 Arm B). All pts 
were caucasian men. Pretreatment characteristics, including age, ECOG 
PS, smoking habits, histological features, and stage were similar
The incidence of acute esophagitis and other radiotherapy related tox-
icities was similar in the two arms of treatment. Detailed information 
about skin toxicity is available for three patienes with 2 patients having 
dermatitis in the radiation area (one arm A one arm B) and one patient 
with an exanthema out of the radiation area (arm B) probably related to 
Erlotinib.
No dose reductions of Erlotinib were necessary. 
Conclusions: The addition of Erlotinib to radiotherapy in the treatment 
of this patients population is feasible and does not appear to increase 
in-ﬁeld toxicities. Data on survival will be presented. Study is ongoing
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Background: The EGFR TK inhibitor erlotinib is approved for the 
treatment of patients with non-small cell lung cancer (NSCLC) as a sin-
gle agent in 2nd and 3rd line treatment. We present data of a prospec-
tive study, which includes unselected chemotherapy-naïve patients not 
suitable for ﬁrst line conventional chemotherapy treated with erlotinib. 
Methods: Eligibility criteria included stage IIIB-IV, conﬁrmed disease, 
PS≤2, age≥18, adequate organ function, and written informed con-
sent. Unselected chemonaïve patients were included for this analysis. 
Erlotinib was administered at a dose of 150 mg/day orally until disease 
progression or withdrawal. Primary objective was to determine time 
to progression. The large subgroup of patients treated as ﬁrst line was 
analyzed to determine the efﬁcacy and safety of erlotinib in this popu-
lation.
Results: 443 patients were included in this subanalysis. Median age 
was 72 years (range (26–90). 59% of the patients were male and 41% 
female and 99% of them were caucasian. Histologies were: adenocar-
cinoma 64%, squamous 16%, large cell 13%, others 7%. Patients who 
had stage IIIB were 24% and 76% had stage IV. Their performance 
status was: PS 0, 19%, PS 1, 51% and PS 2, 30%. Regarding their 
smoking history, 63% of the patients had smoked or are currently 
smokers. 248 patients were evaluable for response, and 6 of them had 
CP, 72 PR and 91 SD. The Response Rate was 31.45% and the Clinical 
Beneﬁt (CR+PR+SD) was 70%. Response Rate was higher in females 
(49.5%, p<0.0001) and in never smokers (16.5% p<0.0001). Median 
time to progression was 6.6 months (95% CI 5.2–8.6).In this population 
the median survival time was 7.1 months (95% CI 6.1–8.4). Regarding 
the safety proﬁle of erlotinib in this population, the main toxicities were 
rash and diarrhea, resulting up to 9% of the patients with grade 3 or 4 
rash, and 2 patients with grade 4 diarrhea. In the multivariate analysis, 
smoking history was the most signiﬁcant predictive factor for TTP and 
survival. 
Conclusions: This result conﬁrms that erlotinib is active when used 
as single agent in ﬁrst line patients with NSCLC in patients that are 
not suitable for chemotherapy. Smoking history is the most signiﬁcant 
predictive factor for TTP and survival. Further studies in this popula-
tion are warranted.
